Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cusatuzumab + Azacitidine in Higher-Risk MDS or CMML
NCT04264806Phase 2Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2021
- Primary completion
- Apr 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of cusatuzumab in myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Janssen Pharmaceutical. Planned start May 2021; status: withdrawn.
02
Drugs
cusatuzumab
03
Conditions
myelodysplastic syndromes (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT04264806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04264806.